Drugs in Dev. Dermatology
Phase I
South Korea 
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : BMI Korea
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Brexogen, BMI Korea Form Exosome Therapy Tech Transfer Deal
Details : Under the icensing agreement, BMI Korea has secured the exclusive rights of BxC-I17e, an innovative exosome-based injectable therapeutics for the treatment of Atopic Dermatitis.
Product Name : BxC-I17e
Product Type : Other Large Molecule
Upfront Cash : $2.3 million
February 19, 2025
Lead Product(s) : BxC-I17e
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : BMI Korea
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : OLX72021
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLX72021 an investigational RNAi therapeutic and acts to suppress the hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor (AR).
Product Name : OLX72021
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : OLX72021
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery.
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 30, 2020
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The purpose of this prospective, randomized, double-blind, intra-subject, placebo-controlled Phase 2a study is to determine the efficacy of OLX10010 in reducing recurrence of hypertrophic scars.
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
